Oral magnesium administration is beneficial in reducing migraine relapse, risk of type 2 diabetes, stroke and hospitalization in pregnant women.
As per the findings of a recently published umbrella review of systematic reviews and meta-analyses of observational and intervention studies, Magnesium (Mg) supplementation provides strong evidence to reduce frequency and intensity of migraine and decreases the risk of hospitalization in pregnant women.
The assessment of meta-analyses of observational studies was done using the random-effects summary effect sizes and their p values, small-study effects and excess significance, heterogeneity, and 95% prediction intervals. Further, a high-GRADE assessment and outcomes with a random-effect p-value < 0.005 were analyzed as strong evidence for the meta-analyses of RCTs.
A total of 55
independent outcomes and 16 meta-analyses were involved. Twelve over 36
outcomes in the RCTs exhibited significant results regarding magnesium as
compared to the placebo or no active treatment. During the GRADE assessment,
strong evidence was found regarding the lowered risk of intensity and frequency
of migraine relapses and reduced necessity for hospitalization in pregnancy.
Further, nine out of nineteen outcomes found to be significant in the case of
observational studies. Although, only one outcome showed suggestively and one
highly suggestive evidence regarding the lower incidence of stroke and lower
incidence of type 2 diabetes among patients taking Mg at the baseline,
respectively. These findings explain a significant role of Mg supplementation
with various health issues.
European Journal of Nutrition
Magnesium and health outcomes: an umbrella review of systematic reviews and meta-analyses of observational and intervention studies.
Nicola Veronese et al.
Comments (0)